Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
moxifloxacin + gatifloxacin
- Development stage
- Unknown
- Lead developer
- Meir Medical Center
- Modality
- Small Molecules
- Administration
- Ophthalmic
01
Overview
moxifloxacin + gatifloxacin refers to the comparative evaluation of two fourth-generation fluoroquinolone antibiotics in a clinical trial conducted by Meir Medical Center. The study was designed as a double-masked, prospective, randomized controlled trial to assess differences in corneal epithelial healing rates and potential epithelial toxicity following pterygium excision surgery. Moxifloxacin (marketed as Vigamox by Alcon) and gatifloxacin (marketed as Zymar by Allergan) are small molecule antibiotics that function by inhibiting bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby preventing bacterial DNA replication and transcription. The trial specifically evaluated these agents as post-operative prophylactic treatments in eyes that had undergone surgery involving the application of Mitomycin C.
- Brand names
- VigamoxZymar
02
Targets
DNA gyraseTopo IV (Bacterial Topoisomerase IV)KCNH2 (Voltage-gated potassium channel subfamily H member 2)
Beyond the preview
Go deeper on moxifloxacin + gatifloxacin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on moxifloxacin + gatifloxacin.